🎯 RRB Exam 24–25 Nov 2026 🏠 Home ℹ️ About Academy 📞 Contact Explore Courses
🏠 Back to Home← Back to Previous Page

Preparing for a pharma job interview? This free handbook gives you 119 interview questions, each with answer guidance and a full example answer across pharmacovigilance, regulatory affairs, clinical research, quality assurance, medical writing, medical affairs, HEOR, medical coding, AI skills, production and hospital pharmacy, plus a glossary. Use the search box to find any question, then open it to read how to answer and an example you can adapt in your own words.

PHARMA INSIGHTS ACADEMY

Pharma Career Skills Handbook

Interview Questions, Model Answers and Core Knowledge for Pharmacists

By Kalai Whani S, Founder, Pharma Insights Academy

Chapter 1

Common Interview Questions for Every Pharmacist

Questions asked in almost every pharmacy interview, whichever field you apply to.

1.1 About You and Your Choices

Keep each answer to 30 to 60 seconds. Replace the bracketed parts with your own facts.

Tell me about yourself.

Give four parts in order: qualification, one academic or project highlight, any practical exposure (internship, training, certification), and why this role. Example: 'I completed B.Pharm from [college] in [year]. My final-year project was on [topic]. I did [internship] where I handled [task]. I am applying here because this role uses [skill] that I want to build.'

Example answer“I completed my B.Pharm from [college] in [year] with [X]%. My final-year project was on the formulation and evaluation of [drug] sustained-release tablets, where I handled the dissolution testing. I also did a one-month internship at [hospital/company] in the [department]. I am applying for this role because it uses my analytical and documentation skills, which I want to build further in a regulated environment.”

Why did you choose pharmacy?

Link an early interest in science or healthcare to something you did that confirmed it, and end with the kind of impact you want to make.

Example answer“In school I enjoyed chemistry and biology, and I saw how much our local pharmacist helped my family understand their medicines. During my internship I counselled patients on inhaler and insulin technique and saw the difference it made to them. That confirmed my choice. I want to work where I can make sure medicines are used safely and correctly.”

Why this field (QA, PV, regulatory, clinical research, sales, hospital)?

Name two features of the field that match your strengths, one thing you did to prepare (course, project, reading), and one thing you still want to learn.

Example answer“I chose Quality Assurance because I am detail-oriented and I enjoy working with systems and documents. QA also lets me see the whole product life cycle, from raw material to batch release. To prepare, I completed a GMP and documentation course and studied the revised Schedule M. I still want to learn how investigations and CAPA are handled in a real plant.”

What are your strengths?

Pick two, each with proof: for example attention to detail shown by error-free dispensing records, and quick learning shown by completing a certification in [weeks].

Example answer“My first strength is attention to detail: during my internship I checked over 200 prescriptions and kept the dispensing register without a single correction. My second is quick learning: I completed a pharmacovigilance certificate course in four weeks while preparing for my final exams.”

What is your weakness?

Choose a genuine but fixable gap such as limited exposure to software or public speaking, and state the step you are taking and the progress made.

Example answer“I have limited hands-on experience with advanced Excel. To fix this, I am taking an online course and practising pivot tables and lookups every week. I have already used them to organise my project data, and I expect to be fully comfortable within the next two months.”

Where do you see yourself in five years?

Describe skill growth and wider responsibility in this field, not a different job title elsewhere.

Example answer“In five years I see myself as a skilled professional in this field, handling tasks independently, training new team members and possibly leading a small team. I want to have a deep knowledge of the guidelines and processes here, and to have contributed to audits or projects that improved quality.”

Why should we hire you?

Match your proven skills to the job description in two points and show readiness to learn the rest.

Example answer“You need someone who understands GMP documentation and can work carefully under deadlines. My project and internship gave me practice in both, and I have completed a certified course in this area. I learn quickly and I am ready to be trained in whatever I do not yet know, so I can contribute from the first month.”

Are you willing to relocate or work in shifts?

Answer honestly; if willing, say so plainly; if there are limits, state them politely with the flexibility you do have.

Example answer“Yes, I am willing to work in rotational shifts, because I understand that production and patient care do not stop. I am also open to relocation; my only request would be a little notice so that I can arrange accommodation.”

Explain your gap year or backlog, if any.

State the reason in one sentence, what you did to stay current, and show that it no longer affects your work.

Example answer“I took one year after my B.Pharm to prepare for GPAT and the government pharmacist exams. During that time I revised core subjects daily and completed an online course in [area]. That year strengthened my basics, and I am now fully focused on starting my career.”

Describe your final-year project.

Cover objective, method, your own role, result and what you learned in about one minute.

Example answer“My project was the formulation and evaluation of fast-dissolving tablets of [drug], aimed at a quicker onset of action. I prepared batches with different superdisintegrants and personally carried out hardness, friability, disintegration and dissolution tests. The best batch disintegrated in under 30 seconds. I learned how small formulation changes affect performance, and how important careful documentation is.”

What is your expected salary?

Say you expect a fair package as per company norms for freshers or for your experience, and that growth and learning matter equally.

Example answer“As a fresher, I am more focused on learning and growth than on the starting figure. I would expect a fair package in line with your company norms and the industry standard for this role. If you need a figure, I understand freshers in this role usually receive [range], and I am comfortable within that.”

1.2 Pharmacy Fundamentals

Difference between a drug, a medicine and a poison?

A drug is any substance that changes body function; a medicine is a drug prepared in a dosage form for treatment or prevention; any substance becomes a poison when dose or exposure is harmful.

Example answer“A drug is any substance that alters body function and is used for diagnosis, prevention or treatment. A medicine is a drug made into a suitable dosage form, like a tablet or syrup, for use in patients. A poison causes harm even in small amounts. As Paracelsus said, the dose makes the poison: even paracetamol is toxic in overdose.”

What is the role of a pharmacist?

To ensure the right drug, dose and duration reach the right patient, with counselling, safe storage, record keeping and monitoring for problems.

Example answer“A pharmacist makes sure the right patient gets the right medicine in the right dose for the right duration. Beyond dispensing, we check prescriptions for errors and interactions, counsel patients, store medicines correctly, keep legal records and report adverse reactions. In hospitals we also support doctors with drug information and rational prescribing.”

Which laws govern pharmacy practice in India?

Pharmacy Act 1948 (education and registration, PCI), Drugs and Cosmetics Act 1940 and Rules 1945, NDPS Act 1985, Drugs and Magic Remedies (Objectionable Advertisements) Act 1954, and the Pharmacy Practice Regulations 2015.

Example answer“The main laws are the Pharmacy Act 1948, which governs education and registration through the PCI; the Drugs and Cosmetics Act 1940 and Rules 1945 for manufacture, sale and distribution; the NDPS Act 1985 for narcotic and psychotropic substances; the Drugs and Magic Remedies Act 1954 for advertisements; and the DPCO 2013 for prices. New drugs and trials come under the NDCT Rules 2019.”

What is a Schedule H drug?

A prescription-only drug that can be sold only on a registered doctor's prescription and must carry the Rx symbol and a warning on the label.

Example answer“A Schedule H drug is a prescription-only medicine. It can be sold by retail only against the prescription of a registered medical practitioner, and its label must carry the Rx symbol with the Schedule H warning. Many antibiotics, antihypertensives and antidiabetics fall in this schedule.”

Schedule H1, X and G in one line each?

H1: certain antibiotics, anti-TB and sedatives sold only on prescription with a separate register kept; X: narcotic and psychotropic drugs with strict licensing, prescription retention and records; G: drugs to be taken only under medical supervision, with a caution on the label.

Example answer“Schedule H1 covers certain newer antibiotics, anti-TB drugs and habit-forming drugs; the pharmacist keeps a separate register with patient, doctor and quantity details for three years. Schedule X covers narcotic and psychotropic drugs such as amphetamine; the prescription is in duplicate and one copy is kept for two years. Schedule G drugs carry the caution that they should be taken only under medical supervision.”

Other schedules often asked?

Schedule M: GMP; Schedule C and C1: biologicals and special products; Schedule J: diseases for which no product may claim cure; Schedule P: shelf life; Schedule K: exemptions; Schedule F: sera, vaccines and blood products.

Example answer“Schedule M lays down Good Manufacturing Practices for premises, equipment and quality systems, and its revised version is now in force. Schedule C and C1 cover biological and special products such as vaccines, sera and insulin. Schedule J lists diseases that no drug may claim to cure, such as cancer and AIDS. Schedule Y covered clinical trials and has been replaced by the NDCT Rules 2019.”

Generic vs branded medicine?

A generic has the same active ingredient, strength and dosage form as the reference brand and must show bioequivalence; the price differs because of brand, marketing and development costs.

Example answer“A generic medicine has the same active ingredient, strength, dosage form and route as the innovator brand, and it must be bioequivalent to it. The differences are usually the name, appearance, excipients and price. Generics cost less because they do not repeat the original research, so schemes like Jan Aushadhi make treatment affordable without compromising quality.”

OTC vs prescription drugs?

OTC drugs are meant for minor, self-recognisable conditions with wide safety margins; prescription drugs need a doctor's diagnosis and supervision.

Example answer“OTC drugs, like paracetamol or antacids, are used for minor conditions that patients can recognise themselves, and they have a wide safety margin. Prescription drugs need a doctor's diagnosis and monitoring because of risks such as toxicity, resistance or dependence; antibiotics are a good example. Even for OTC products, I would counsel the patient on dose and warning signs.”

What is the Essential Medicines List?

A list of medicines that satisfy priority health needs, selected for efficacy, safety and cost-effectiveness; India has a National List of Essential Medicines (NLEM) which also guides price control.

Example answer“The Essential Medicines List contains medicines that meet the priority health needs of the population, chosen for efficacy, safety and cost-effectiveness. WHO updates its Model List every two years, and India has its own National List of Essential Medicines; NLEM 2022 lists 384 medicines. NLEM medicines are price-controlled under the DPCO.”

What are FIFO and FEFO?

First In First Out and First Expired First Out stock rotation; FEFO is preferred for medicines so that the earliest-expiring stock goes first.

Example answer“FIFO means stock received first is issued first. FEFO means stock that expires first is issued first, whatever its arrival date. For medicines FEFO is preferred, because a newer batch can sometimes have an earlier expiry. In practice, I keep the nearest-expiry stock in front and check expiry dates every month.”

Common storage terms?

Cold: 2 to 8 °C; cool: 8 to 25 °C; room temperature: usual ambient; freezer: below minus 10 °C; protect from light and moisture where stated.

Example answer“As per the pharmacopoeia, cold means 2 to 8 °C, used for insulin and vaccines; cool means 8 to 25 °C; room temperature is the temperature of the working area; and a freezer is between minus 25 and minus 10 °C. I also check the label for instructions such as 'protect from light' and 'store in a dry place'.”

Expiry vs manufacturing date?

Manufacturing date is when the batch was made; expiry is the last date up to which the manufacturer guarantees potency and safety under stated storage.

Example answer“The manufacturing date is when the batch was produced. The expiry date is the last date up to which the manufacturer guarantees strength, quality and purity, provided the product is stored as labelled. If the label says Exp 06/2027, it can be used until the end of June 2027. Expired stock must be separated and returned or destroyed, never sold.”

Parts of a prescription?

Patient details, date, Rx symbol, drug name, strength, dosage form, dose, frequency, route, duration, doctor's name, registration number and signature.

Example answer“A complete prescription has the doctor's name, qualification and registration number; the date; the patient's name, age, sex and address; the Rx symbol; the drug name, strength and dosage form; the quantity; directions to the patient, covering dose, frequency, route and duration; and the doctor's signature.”

Common prescription abbreviations?

OD once daily, BD twice daily, TDS thrice daily, QID four times daily, HS at bedtime, SOS if needed, AC before meals, PC after meals, STAT immediately.

Example answer“OD is once daily, BD twice daily, TDS three times daily and QID four times daily. HS means at bedtime, SOS if required and STAT immediately. AC is before food and PC after food. I always confirm an unclear abbreviation with the doctor, because a misread abbreviation can cause a dosing error.”

Which pharmacopoeias are used?

Indian Pharmacopoeia (IP) in India, British Pharmacopoeia (BP), United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and International Pharmacopoeia (WHO).

Example answer“In India we follow the Indian Pharmacopoeia, published by the Indian Pharmacopoeia Commission, Ghaziabad. Internationally, the main ones are the British Pharmacopoeia, the United States Pharmacopeia–National Formulary, the European Pharmacopoeia and the Japanese Pharmacopoeia. Export products are tested to the pharmacopoeia of the importing country.”

1.3 Core Pharmacology and Pharmaceutics

What is bioavailability and bioequivalence?

Bioavailability is the rate and extent to which the active drug reaches systemic circulation; two products are bioequivalent when their bioavailability is not significantly different under the same conditions.

Example answer“Bioavailability is the rate and extent to which the active drug reaches systemic circulation; an intravenous dose has 100% bioavailability. Two products are bioequivalent when their rate and extent of absorption are similar: the 90% confidence interval for the ratio of AUC and Cmax must fall within 80 to 125%. That is how a generic proves it matches the brand.”

What is half-life and why does it matter?

Time taken for plasma concentration to fall by half; it decides dosing interval and the time to reach steady state (about four to five half-lives).

Example answer“Half-life is the time taken for the plasma concentration of a drug to fall by half. It decides how often the drug is given, and a drug reaches steady state after about four to five half-lives; it is also almost fully eliminated in that time after stopping. A drug with a short half-life may need several doses a day or a sustained-release form.”

What is first-pass metabolism?

Drug metabolism in the gut wall and liver before reaching systemic circulation, which lowers oral bioavailability of some drugs, for example propranolol and nitroglycerin.

Example answer“First-pass metabolism is the breakdown of an oral drug in the gut wall and liver before it reaches systemic circulation, which lowers its oral bioavailability. Glyceryl trinitrate is a classic example, which is why it is given sublingually. Sublingual, transdermal and intravenous routes avoid or reduce first-pass metabolism.”

Define therapeutic index.

Ratio between the toxic (or lethal) dose and the effective dose; a narrow index means close monitoring, as with digoxin, warfarin, lithium and phenytoin.

Example answer“Therapeutic index is the ratio of the toxic dose to the effective dose, classically TD50 divided by ED50. A high index means a wide safety margin. Drugs with a narrow index, such as digoxin, lithium, warfarin and phenytoin, need careful dosing and therapeutic drug monitoring.”

Side effect vs adverse drug reaction vs toxicity?

Side effect: unintended but expected effect at therapeutic dose; ADR: any harmful, unintended response at normal doses; toxicity: harm from excess dose or accumulation.

Example answer“A side effect is an unintended but expected effect at a normal dose, such as drowsiness with older antihistamines. An adverse drug reaction is any harmful, unintended response at normal doses, such as a rash with penicillin. Toxicity is harm from an excessive dose or accumulation, such as liver damage after a paracetamol overdose.”

Types of drug interactions?

Pharmaceutical (physical or chemical incompatibility), pharmacokinetic (absorption, distribution, metabolism, excretion), and pharmacodynamic (additive, synergistic, antagonistic).

Example answer“There are three types. Pharmaceutical interactions are physical or chemical incompatibilities outside the body, for example in an IV mixture. Pharmacokinetic interactions change absorption, distribution, metabolism or excretion, for example enzyme induction by rifampicin. Pharmacodynamic interactions happen at the site of action, where effects add up or oppose each other, for example two sedatives causing excess drowsiness.”

Examples of clinically important interactions?

Warfarin with aspirin or NSAIDs (bleeding), ciprofloxacin with antacids (reduced absorption), rifampicin with oral contraceptives (reduced effect), clarithromycin with statins (myopathy).

Example answer“Warfarin with aspirin or NSAIDs raises bleeding risk. Ciprofloxacin taken with antacids or iron is poorly absorbed because of chelation. Rifampicin induces liver enzymes and reduces the effect of oral contraceptives. Clarithromycin with simvastatin increases the risk of myopathy, and sildenafil with nitrates can cause severe hypotension.”

Calculate a child's dose by Young's rule.

Child dose = age in years ÷ (age + 12) × adult dose; weight-based dosing is preferred where available.

Example answer“Young's rule is: child's dose equals age in years divided by age plus 12, multiplied by the adult dose. For a 6-year-old with an adult dose of 300 mg, that is 6 ÷ 18 × 300, which is 100 mg. It applies to children aged 1 to 12. In practice I prefer weight-based or body surface area dosing wherever it is available.”

Sterile vs non-sterile dosage forms?

Sterile forms (injections, eye drops, irrigations) are free from viable microorganisms and made in controlled areas; non-sterile forms (tablets, syrups) have microbial limits but need not be sterile.

Example answer“Sterile dosage forms, like injections, eye drops and irrigation fluids, must be free from viable microorganisms. They are made in classified cleanrooms by aseptic processing or terminal sterilisation, and tested for sterility, endotoxins and particulate matter. Non-sterile forms like tablets and syrups only need to meet microbial limits.”

Why are some tablets enteric coated?

To protect acid-labile drugs from gastric acid or protect the stomach from irritant drugs, for example aspirin, diclofenac and pantoprazole.

Example answer“Enteric coating is a polymer coat that resists stomach acid and dissolves at the higher pH of the intestine. It protects acid-labile drugs like omeprazole, or protects the stomach from irritant drugs like aspirin and diclofenac. That is why enteric-coated tablets should not be crushed or chewed.”

Common routes of administration with one example each?

Oral, sublingual (glyceryl trinitrate), intravenous, intramuscular, subcutaneous (insulin), transdermal (nicotine patch), inhalation (salbutamol), topical, rectal.

Example answer“Oral, like paracetamol tablets; sublingual, like glyceryl trinitrate; intravenous, like normal saline; intramuscular, like many vaccines; subcutaneous, like insulin; transdermal, like nicotine patches; inhalation, like salbutamol inhalers; topical, like clotrimazole cream; and rectal, like bisacodyl suppositories.”

What does GxP mean?

The family of 'good practice' standards: GMP for manufacturing, GLP for laboratories, GCP for clinical trials, GDP for distribution and GVP for pharmacovigilance.

Example answer“GxP is the family of good practice guidelines that keep products safe and data reliable. It includes GMP for manufacturing, GLP for non-clinical laboratory studies, GCP for clinical trials, GDP for distribution and GVP for pharmacovigilance. The common idea is: document what you do, do what you document, and keep everything traceable.”

1.4 Behavioural and Ethical Questions

A customer asks for an antibiotic without a prescription. What do you do?

Explain that it is a prescription-only drug, ask about symptoms, advise seeing a doctor and offer safe symptomatic relief if appropriate; do not dispense.

Example answer“I would politely explain that antibiotics are prescription-only medicines and that the wrong one can cause side effects and resistance. I would ask about the symptoms and advise a doctor's visit, especially if there is fever or the problem has lasted several days. Meanwhile I can suggest safe relief, such as paracetamol for fever, fluids and rest.”

How do you handle pressure and deadlines?

Prioritise by urgency and patient impact, keep a written list, communicate delays early, and double-check critical steps.

Example answer“I first list my tasks and rank them by urgency and impact on the patient or product. I break big tasks into steps and keep a checklist. If a deadline is slipping, I tell my supervisor early rather than at the last minute. Even under pressure, I never skip the double-check on critical steps. This helped me submit my project on time during my final exams.”

Tell me about a conflict with a colleague.

Describe the issue neutrally, how you listened and proposed a common goal, and the outcome; avoid blaming.

Example answer“During my project, a teammate and I disagreed on which analytical method to use. Instead of arguing, I asked him to explain his reasons, and we listed the pros and cons of both. We agreed to run a small trial of each and let the data decide. His method worked better, we used it, and we submitted on time. I learned to focus on the shared goal.”

You realise you made an error. What next?

Inform the supervisor immediately, protect the patient or product, correct the record properly, and put a safeguard in place.

Example answer“I would inform my supervisor immediately, even if the error seems small. First I would protect the patient or product, for example by contacting the patient or quarantining the batch. Then I would correct the record properly with a single line, date and signature, never by overwriting. Finally I would help find the root cause so it does not happen again.”

How do you keep learning?

Follow regulator notices and journals, take short certified courses, and review one new topic each week.

Example answer“I follow CDSCO notices, PvPI updates and Indian Pharmacopoeia Commission announcements. I take short certified online courses; recently I completed one on [topic]. Every week I pick one new topic, read a guideline or review article on it and make short notes, and I discuss updates with seniors.”

What if a doctor's prescription looks unsafe?

Verify with the doctor politely, document the clarification, and dispense only after resolution.

Example answer“I would not dispense it straight away. I would politely contact the doctor, explain my concern, for example a dose higher than usual or an interaction with another drug, and ask for confirmation or a change. I would record the conversation and outcome, dispense only after it is resolved, and explain any change to the patient.”

Which software or tools do you know?

State honestly: MS Office, pharmacy management software, drug databases, and any course tools; add what you are learning.

Example answer“I am comfortable with MS Word, Excel and PowerPoint, and I used pharmacy billing and inventory software during my internship. I refer to drug information sources such as CIMS, Medscape and the Indian Pharmacopoeia. I have basic exposure to [tool] from my certification course, and I am currently improving my Excel skills.”

Do you have any questions for us?

Ask about training plan, team structure, performance expectations in the first six months and growth path.

Example answer“Yes, thank you. Could you tell me what the training plan looks like for a new joinee in this role? What would you expect me to achieve in the first six months? And how is the team structured, and what growth path have others in this role followed?”

Chapter 2

Pharmacovigilance and Drug Safety

Detecting, assessing, understanding and preventing adverse effects of medicines.

2.1 Basics and History

  • WHO definition: the science and activities relating to detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
  • The thalidomide tragedy of the early 1960s led to modern systems for monitoring drug safety.
  • WHO Programme for International Drug Monitoring is coordinated by the Uppsala Monitoring Centre; the global database is VigiBase.
  • Aims: patient safety, early signal detection, benefit-risk assessment, regulatory compliance and communication of risk.
  • India: Pharmacovigilance Programme of India (PvPI) works through the Indian Pharmacopoeia Commission, Ghaziabad, as National Coordination Centre with ADR Monitoring Centres at medical colleges and hospitals.

2.2 Key Terms

TermMeaning
Adverse Event (AE)Any untoward medical occurrence after a medicine is given, whether or not caused by it
Adverse Drug Reaction (ADR)A noxious and unintended response to a drug at normal doses, with a causal possibility
SeriousResults in death, life threat, hospitalisation or prolonged stay, persistent disability, congenital anomaly or is medically important
UnexpectedNature or severity not in the reference safety information (label or IB)
Listed / labelledAlready described in the product label
Suspect and concomitant drugDrug thought to cause the event vs other drugs taken at the same time
Dechallenge / rechallengeEvent outcome after stopping / restarting the drug
Medication errorPreventable event in prescribing, dispensing or use of a medicine

2.3 Classification of ADRs

Type (Rawlins-Thompson)FeaturesExample
A: AugmentedDose-related, predictable, common, low mortalityHypoglycaemia with insulin
B: BizarreNot dose-related, unpredictable, rare, seriousAnaphylaxis to penicillin
C: ChronicRelated to cumulative dose over long timeAdrenal suppression with steroids
D: DelayedAppears long after exposureTeratogenicity, secondary cancers
E: End of useOccurs on withdrawalRebound hypertension after clonidine
F: Failure of therapyUnexpected lack of effectInteraction reducing efficacy

2.4 Individual Case Safety Report (ICSR)

  • A valid ICSR needs four minimum elements: an identifiable patient, an identifiable reporter, at least one suspect drug and at least one adverse event.
  • Sources: spontaneous reports, clinical trials, literature, regulatory authorities, patient support programmes, social media and market research.
  • Reporters: healthcare professionals, consumers, other companies and authorities.
  • Day zero (clock start) is the first date the company receives all four minimum criteria.
  • Follow-up information is sought for missing or unclear details.

2.5 Case Processing Workflow

StepActivity
1. IntakeReceive and log source documents; check validity
2. TriageSeriousness, expectedness and timeline priority
3. Data entryEnter patient, drug, event, history and narrative fields in the safety database
4. CodingCode events in MedDRA and drugs in WHODrug
5. Causality and listednessAssess relationship and label expectedness
6. Narrative writingWrite a concise chronological case summary
7. Medical reviewPhysician checks seriousness, causality and company comment
8. SubmissionReport to authorities, partners, ethics committees as per timelines
9. Follow-up and archiveUpdate the case and archive with audit trail

2.6 MedDRA and WHODrug

  • MedDRA (Medical Dictionary for Regulatory Activities) is the standard terminology for events; maintained by MSSO and updated twice a year.
  • Five levels from specific to general: Lowest Level Term (LLT), Preferred Term (PT), High Level Term (HLT), High Level Group Term (HLGT), System Organ Class (SOC).
  • Coding rule: code the reported term as faithfully as possible, to the most specific suitable term; do not add diagnoses not stated.
  • Standardised MedDRA Queries (SMQs) group terms for a medical concept, used in signal detection.
  • WHODrug Global is the dictionary for medicinal products and ingredients (ATC classification).

2.7 Causality Assessment

ToolCategories / scoring
WHO-UMCCertain, Probable/Likely, Possible, Unlikely, Conditional/Unclassified, Unassessable/Unclassifiable
Naranjo scale10 questions: 9 or more definite; 5 to 8 probable; 1 to 4 possible; 0 or less doubtful
  • Factors weighed: time relationship, dechallenge, rechallenge, alternative causes, known pharmacology, concomitant drugs and underlying disease.
  • Seriousness is about outcome; severity is about intensity; do not confuse them.

2.8 Reporting Timelines (Typical)

ReportTypical timeline
Clinical trial SUSAR, fatal or life-threatening7 calendar days initial, complete information in a further 8 days
Clinical trial SUSAR, other15 calendar days
Post-marketing serious unexpected / expedited case15 calendar days from day zero
India: SAE in a trialInvestigator to sponsor, ethics committee and licensing authority within 24 hours; sponsor report to the authority within 14 days
Non-serious casesReported in periodic reports, or monthly in some regions
  • Always confirm the current rule in the regional regulation; timelines are revised from time to time.

2.9 Aggregate Reports and Risk Management

ReportPurpose
PSUR / PBRER (ICH E2C R2)Periodic benefit-risk evaluation of a marketed product
DSUR (ICH E2F)Annual safety review of an investigational product
RMPPlan listing safety concerns, pharmacovigilance and risk minimisation activities
PADER (USA)Periodic adverse drug experience report
ACO / signal reportsAd hoc assessments of a specific safety question
  • In India, PSURs for new drugs are generally due every six months for the first two years and yearly for the next two years after approval.
  • Risk minimisation can be routine (label, pack) or additional (educational material, controlled access).

2.10 Signal Detection

  • A signal is information suggesting a new or changed causal link between a drug and an event that warrants further investigation.
  • Quantitative methods use disproportionality: Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Empirical Bayes Geometric Mean (EBGM) and the Information Component (IC).
  • Qualitative review of case series looks at temporal link, dechallenge, plausibility and alternative causes.
  • Steps: detect, validate, analyse and prioritise, assess, recommend action, communicate and track.
  • Possible actions: continue monitoring, label update, additional studies, restriction, withdrawal.

2.11 Clinical Trial Safety

  • Sponsor evaluates every SAE for causality and expectedness against the Investigator's Brochure.
  • SUSARs are expedited to authorities, ethics committees and investigators.
  • Safety reconciliation matches the safety database with the clinical database before database lock.
  • DSMB reviews unblinded safety data periodically.
  • Pregnancy exposure, overdose, misuse and lack of efficacy are handled as special situations.

2.12 Post-Marketing Safety Activities

  • Spontaneous reporting, literature screening (weekly in many companies), social media and web monitoring.
  • Patient support and market research programmes are checked for safety information.
  • Active surveillance: registries, prescription-event monitoring, observational studies.
  • Safety communications: Dear Healthcare Professional Letters, label changes, safety alerts.
  • Duplicate detection and case merging avoid double counting.

2.13 Regulations and Guidelines

RegionKey reference
ICHE2A (expedited reporting), E2B (R3) data elements, E2C (R2), E2D (post-approval), E2E (planning), E2F (DSUR), M1 MedDRA
EUGood Pharmacovigilance Practices (GVP) modules; EudraVigilance
USA21 CFR 312.32 and 314.80; FAERS; MedWatch
IndiaSchedule Y replaced by New Drugs and Clinical Trials Rules 2019; Good Pharmacovigilance Practices for Indian pharma industry; PvPI guidance
WHOVigiBase, WHO-UMC causality method, Uppsala reporting tools

2.14 Safety Databases and Tools

  • Commercial safety databases: Oracle Argus, ArisG, Veeva Vault Safety; used for case intake, coding, workflow, reporting and audit trail.
  • E2B(R3) is the electronic format for transmitting ICSRs between companies and regulators.
  • Dictionaries: MedDRA and WHODrug; signal tools such as Empirica Signal.
  • Systems must be validated, access-controlled and have audit trails (21 CFR Part 11, Annex 11).
  • AI and natural language processing now help with case intake, duplicate checking and literature screening, with human review retained.

2.15 Reporting an ADR in India

  • Healthcare professionals and patients can report by filling the Suspected Adverse Drug Reaction Reporting Form or by using the PvPI mobile app or helpline 1800-180-3024.
  • Reports go to the nearest ADR Monitoring Centre; the National Coordination Centre sends them to the WHO database.
  • Pharmacists should report any suspected reaction, even if unsure of causality.
  • Counselling points: explain common side effects, what to do if one occurs, and when to contact the doctor.

2.16 Quality and Inspection in PV

  • Pharmacovigilance System Master File (PSMF) describes the PV system (EU requirement).
  • Qualified Person Responsible for Pharmacovigilance (QPPV) is accountable for the system.
  • Quality indicators: on-time submissions, case quality, follow-up success, backlog.
  • Common inspection findings: late reporting, missing literature screening, weak reconciliation, poor documentation and unvalidated systems.

2.17 Quick Interview Questions

Define pharmacovigilance in simple words.

Watching how medicines behave after they reach patients so that harm is found early and prevented.

Example answer“Pharmacovigilance is the science of detecting, assessing, understanding and preventing adverse effects of medicines. In simple words, it means watching how medicines behave once they reach real patients, so that harm is found early and prevented. In India this is done through the Pharmacovigilance Programme of India, coordinated by the IPC.”

What are the minimum criteria for a valid ICSR?

Identifiable patient, identifiable reporter, suspect drug and adverse event.

Example answer“A valid ICSR needs four minimum criteria: an identifiable patient, an identifiable reporter, at least one suspect drug and at least one adverse event. If any one is missing, the case is not yet valid, and we keep following up to obtain the missing information.”

Difference between AE and ADR?

An AE need not be caused by the drug; an ADR has at least a reasonable possibility of being caused by it.

Example answer“An adverse event is any untoward medical occurrence in a patient taking a drug, whether or not the drug caused it. An adverse drug reaction is one where there is at least a reasonable possibility that the drug caused it. So every ADR is an AE, but not every AE is an ADR; a fracture from a road accident during a trial is an AE but probably not an ADR.”

Seriousness vs severity?

Seriousness is based on outcome or criteria such as hospitalisation; severity describes intensity such as mild or severe.

Example answer“Seriousness is based on outcome: death, a life-threatening event, hospitalisation or its prolongation, persistent disability, congenital anomaly, or another medically important event. Severity describes intensity: mild, moderate or severe. A severe headache may not be serious, while a mild event that leads to hospitalisation is serious. Seriousness decides the reporting timelines.”

What is expectedness?

Whether the event is already described in the reference safety information of the product.

Example answer“Expectedness tells us whether the event is already listed in the product's reference safety information, such as the Investigator's Brochure during trials or the prescribing information after marketing. If the event, or its severity, is not listed, it is unexpected. A serious, unexpected and related event in a trial is a SUSAR and needs expedited reporting.”

What is MedDRA and how many levels?

Standard medical terminology for regulatory use with five levels: LLT, PT, HLT, HLGT, SOC.

Example answer“MedDRA is the Medical Dictionary for Regulatory Activities, developed under ICH. It has five levels: Lowest Level Term, Preferred Term, High Level Term, High Level Group Term and System Organ Class. We code the reported term at LLT level, and analysis is usually done at PT and SOC level. It is updated twice a year.”

Explain Naranjo scale.

A ten-question scoring tool for ADR causality; total score decides doubtful, possible, probable or definite.

Example answer“The Naranjo scale is a ten-question tool for ADR causality. The questions cover timing, dechallenge, rechallenge, alternative causes and objective evidence. A total score of 9 or more is definite, 5 to 8 probable, 1 to 4 possible and 0 or less doubtful. In India the WHO-UMC scale is also widely used.”

What is a signal?

New or changed information on a possible causal link that needs further evaluation.

Example answer“A signal is information from one or more sources that suggests a new possible causal link between a drug and an event, or a new aspect of a known link, which needs further evaluation. It can come from spontaneous reports, literature or trials. A signal is not proof; it goes through validation, prioritisation and assessment before any action is taken.”

What is a PSUR / PBRER?

A periodic report that reviews the benefit-risk balance of a marketed medicine using all safety data in the period.

Example answer“A PSUR, now called a PBRER under ICH E2C(R2), is a periodic report that evaluates the benefit-risk balance of a marketed product. It summarises worldwide safety data, new signals, patient exposure and relevant efficacy information for the reporting interval, and concludes whether the benefit-risk remains favourable or label changes are needed.”

What is day zero?

The date when the company first receives the four minimum criteria of a case.

Example answer“Day zero is the date when anyone in the company, or its partner, first receives information that meets all four minimum criteria of a valid case. Reporting timelines start from that day, for example 15 calendar days for serious unexpected reactions. That is why every employee, including field staff, must forward safety information immediately.”

How do you handle a case with no suspect drug?

It is not a valid ICSR; seek follow-up and record the attempts.

Example answer“Without a suspect drug the case does not meet the minimum criteria, so it is not yet a valid ICSR. I would not discard it; I would record it, send follow-up requests to the reporter to identify the product, and document each attempt. If the drug is identified later, day zero starts when that information is received.”

Role of a pharmacist in PV?

Identify, record and report suspected ADRs, counsel patients and support safe use.

Example answer“The pharmacist is often the first to hear about a reaction. Our role is to identify suspected ADRs, collect details, fill the Suspected ADR Reporting Form and send it to the nearest ADR Monitoring Centre or through the PvPI helpline or app. We also counsel patients about side effects and how to report them.”

Chapter 3

Regulatory Affairs

Getting a medicine approved, keeping it compliant, and keeping it on the market.

3.1 What Regulatory Affairs Does

  • Acts as the link between a company and health authorities such as CDSCO (India), USFDA, EMA and WHO.
  • Plans the approval route for each product and country before development is complete.
  • Compiles, checks and files dossiers (applications) and tracks them until a decision.
  • Answers authority queries and deficiency letters within fixed timelines.
  • Handles label changes, post-approval changes, renewals and licence maintenance.
  • Advises R&D, manufacturing and marketing on what is allowed and what is not.

3.2 Major Regulatory Authorities

RegionAuthorityKey legal basis / note
IndiaCDSCO / DCGIDrugs and Cosmetics Act 1940; New Drugs and Clinical Trials Rules 2019
USAFDAFederal Food, Drug and Cosmetic Act; Code of Federal Regulations (CFR)
European UnionEMA with national agenciesCentralised, decentralised and mutual-recognition routes
United KingdomMHRASeparate national system after Brexit
GlobalWHOPrequalification and guidance used by many countries

3.3 Types of Applications

TermFull formPurpose
INDInvestigational New Drug applicationPermission to start human trials in the USA
NDANew Drug ApplicationMarketing approval for a new drug (USA)
ANDAAbbreviated New Drug ApplicationGeneric approval by showing bioequivalence to the reference product
505(b)(2)Hybrid NDA pathwayNew product that relies partly on data the applicant did not generate (new salt, dosage form, strength)
MAAMarketing Authorisation ApplicationApproval to market in the EU
BLABiologics License ApplicationApproval route for biological products in the USA

3.4 CTD and eCTD

The Common Technical Document is one agreed dossier layout accepted by many regulators. The eCTD is its electronic version with a defined folder and lifecycle structure.

ModuleContent
Module 1Regional administrative and prescribing information (differs by country)
Module 2Overall summaries: quality, non-clinical overview, clinical overview
Module 3Quality: chemistry, manufacturing and controls (CMC)
Module 4Non-clinical study reports: pharmacology and toxicology
Module 5Clinical study reports: safety and efficacy
  • Only Modules 2 to 5 are common to all regions; Module 1 is always region-specific.
  • eCTD allows later sequences (variations, responses) to be added without refiling everything.

3.5 ICH Guidelines

ICH brings regulators and industry together to harmonise technical requirements so one set of studies serves several markets.

SeriesThemeExamples
QQualityQ1 stability, Q3 impurities, Q8 development, Q9 risk management, Q10 quality system
SSafety (non-clinical)S1 carcinogenicity, S7 safety pharmacology
EEfficacy (clinical)E3 study report format, E6 Good Clinical Practice
MMultidisciplinaryM4 CTD, M1 MedDRA terminology

3.6 Clinical Trial Phases and Regulatory Touchpoints

PhaseMain aimRegulatory work
Phase ISafety, tolerability, dose rangeTrial approval, ethics clearance, safety reporting set-up
Phase IIEarly efficacy, side effects, dose selectionProtocol amendments, safety updates
Phase IIIConfirm efficacy and monitor adverse reactions at scalePre-submission meetings, dossier preparation
Phase IVLong-term safety after approvalPeriodic safety reports, label updates

3.7 Post-Approval Changes

  • Any change to an approved product (site, process, specification, pack, label) must be assessed before it is made.
  • Changes are classified by risk: minor, moderate or major; the class decides whether prior approval is needed.
  • USA uses supplements (prior approval, CBE-30, CBE-0, annual report); EU uses Type IA, IB and II variations.
  • A change comparability or stability data package usually supports the filing.
  • Internal teams are told the effective date so that old and new material are not mixed.

3.8 Expedited Programmes (FDA)

ProgrammeIdea
Fast TrackMore frequent FDA contact and rolling submission for serious conditions
Breakthrough TherapyIntensive guidance when early data show a substantial advantage over existing therapy
Priority ReviewShortens the review goal to about 6 months instead of about 10 for standard review
Accelerated ApprovalApproval on a surrogate endpoint; confirmatory trials are mandatory after approval
  • Conditional marketing authorisation in the EU works on a similar principle for unmet medical needs.

3.9 Orphan Drugs

  • Orphan status is given to medicines for rare diseases; in the USA, a condition affecting fewer than 200,000 people.
  • Incentives include fee waivers, tax credit on clinical costs and a period of market exclusivity (7 years in the USA).
  • The aim is to make development commercially workable for small patient groups.

3.10 Safety Obligations

  • Pharmacovigilance: detecting, assessing and preventing adverse effects after marketing.
  • Risk Management Plan (RMP): lists known and potential risks and how each will be monitored and minimised.
  • REMS (USA): extra controls such as restricted distribution or patient registries for drugs with serious risks.
  • Regulatory Affairs ensures that periodic safety reports and urgent reports reach authorities on time.

3.11 Inspection Readiness and Recalls

  • Run mock inspections and close the findings before the real visit.
  • Keep records current; nominate a person for each area who can retrieve documents quickly.
  • Train staff to answer only what is asked, factually, and to escalate unknowns.
  • Recall steps: stop distribution, notify authority, trace and retrieve batches, communicate to stakeholders, investigate root cause, verify effectiveness.

3.12 Other Topics to Know

  • 21 CFR Part 11: rules for electronic records and signatures (validated systems, access control, audit trails).
  • Orange Book: FDA list of approved drugs with therapeutic equivalence ratings, patents and exclusivities.
  • GDUFA / PDUFA: user-fee laws that fund FDA review and set review time goals.
  • Combination products (drug plus device) need coordinated drug and device regulatory input.
  • Real-world evidence supports label expansion and post-marketing commitments.
  • Bridging studies justify using foreign data in a new population or region.

3.13 Quick Interview Questions

How do you prepare a dossier for several countries?

Build the core in CTD format, keep a tracker of country-wise Module 1 needs, review each market's local rules, and file in the order that suits timelines.

Example answer“I would first prepare the core dossier in CTD format, Modules 2 to 5, which most markets accept. Then I would build a tracker of each country's Module 1 needs, such as forms, labelling, local stability data and fees. I would do a gap analysis per market, close the gaps, and keep strict version control so each country gets the right documents.”

What is the difference between IND and NDA?

IND lets human trials begin; NDA asks for permission to sell after trials prove safety and efficacy.

Example answer“An IND, or Investigational New Drug application, is filed with the FDA to get permission to start human clinical trials. An NDA, or New Drug Application, is filed after the trials with full safety, efficacy and quality data to get approval to market the drug. In India, trial and marketing permissions are granted under the NDCT Rules 2019.”

What do you do on receiving a deficiency letter?

Classify queries by priority, collect data from the owning teams, write an evidence-based reply and submit before the deadline.

Example answer“I would read the letter carefully, list each query and rank it by priority and deadline. Then I would assign each query to the right team, such as QC for analytical data or R&D for formulation, and track progress. I would write a clear, evidence-based reply to each point, get it reviewed and submit before the deadline, requesting an extension early if needed.”

How do you stay current with guidelines?

Follow official websites and notices, review guideline updates monthly, and maintain a tracked checklist.

Example answer“I follow updates from CDSCO, USFDA, EMA and ICH and check their websites every week. Each month I review new or revised guidelines and note what affects our products. I keep a checklist of each change with its impact and the action required, and share it with my team. I also attend webinars and short courses.”

Difference between ANDA and 505(b)(2)?

ANDA shows bioequivalence only; 505(b)(2) is a full application that borrows part of its evidence.

Example answer“An ANDA is for a generic copy of a reference drug; it does not repeat safety and efficacy studies and relies on bioequivalence. A 505(b)(2) is a full NDA where part of the evidence comes from studies the applicant did not conduct, such as published literature. It is used for changes like a new dosage form, strength or combination.”

What is a CRL?

A Complete Response Letter lists reasons the FDA cannot approve yet; the sponsor fixes the issues and resubmits.

Example answer“A Complete Response Letter is issued by the FDA when an application cannot be approved in its present form. It lists the deficiencies, such as missing data or inspection findings. The sponsor can resubmit after addressing them, or withdraw the application. I would treat each deficiency as a task with an owner and a timeline.”

Why is a gap analysis done?

To compare an existing dossier against a new market's requirements and plan the missing work.

Example answer“A gap analysis compares an existing dossier with the requirements of a new market or a revised guideline. It shows which data are acceptable, which need updating and which are missing, such as local stability data or bioequivalence against the local reference product. This helps us plan the work, timelines and cost before filing.”

How would you handle a late data request before submission?

Prioritise, split what can be supplied now from what cannot, inform the authority early and ask for extension only if needed.

Example answer“I would assess the request quickly and separate what we can provide now from what needs more time, such as new stability or testing data. I would inform my manager and the authority early, submit what is ready, and give a realistic date for the rest, requesting an extension if needed. Being transparent protects our credibility.”

Chapter 4

Clinical Research

How human trials are designed, run and documented so that results can be trusted.

4.1 Key Roles

RoleResponsibility
SponsorStarts, funds and takes overall responsibility for the trial
CROOrganisation hired by the sponsor to run part or all of the work
Principal InvestigatorDoctor accountable for the study at a site and for participant care
CRA / MonitorVisits sites to check protocol and GCP compliance and data accuracy
CRC / Study CoordinatorSite staff who handle daily study activities and records
Data Manager / BiostatisticianClean, lock and analyse the data
Ethics CommitteeIndependent body protecting participants' rights and safety

4.2 Phases of a Trial

PhaseParticipantsFocus
ISmall group, often healthy volunteersSafety, dose and how the body handles the drug
IIPatients, tens to a few hundredEarly effectiveness, side effects, best dose
IIILarge patient groupsConfirm benefit, compare with standard care, collect safety data
IVMarketed useLong-term safety and real-use effectiveness

4.3 Good Clinical Practice (GCP)

GCP (ICH E6) is the international ethical and scientific standard for trials.

  • Participant rights, safety and well-being outweigh the interests of science and society.
  • A trial begins only when expected benefit justifies risk.
  • Every trial follows a written protocol approved by an ethics committee.
  • Medical care of participants is the responsibility of a qualified doctor.
  • Each team member is trained and qualified for their task.
  • Informed consent is freely given before any study procedure.
  • All clinical information is recorded, handled and stored so it can be verified.
  • Participant confidentiality is protected.

4.4 Core Study Documents

DocumentPurpose
ProtocolObjectives, design, eligibility, procedures, endpoints, statistics
Investigator's Brochure (IB)Summary of non-clinical and clinical data on the investigational product
Informed Consent Form (ICF)Plain-language explanation of the study for participants
Case Report Form (CRF)Standard form to capture each participant's data
Statistical Analysis Plan (SAP)Fixes the analysis methods before data are unblinded
Trial Master File (TMF)Complete set of essential documents proving GCP compliance
Clinical Study Report (CSR)Final report of design, conduct and results (ICH E3 format)

4.5 Informed Consent

  • Given in a language the participant understands; time is allowed to ask questions and decide.
  • ICF covers purpose, procedures, risks, benefits, alternatives, confidentiality, compensation and the right to withdraw without penalty.
  • Signed and dated before any trial-specific procedure.
  • Re-consent is needed when new information affects willingness to continue.
  • For participants unable to consent, a legally acceptable representative signs, with an impartial witness where required.
  • In India, audio-visual recording of the consent process is required for trials under NDCT Rules 2019.

4.6 Trial Design Concepts

ConceptMeaning
RandomisationRandom assignment to groups to avoid selection bias
BlindingHiding treatment allocation (single, double) to avoid observation bias
Placebo controlInactive comparator used to separate drug effect from expectation
Non-inferiorityShows a new treatment is not worse than standard by a set margin
Adaptive designPre-planned changes (dose, sample size) based on interim data
Observational vs interventionalObserve only vs assign an intervention
Interim analysisPlanned look at partial data for safety, futility or early benefit

4.7 Safety Reporting

TermMeaning
Adverse Event (AE)Any untoward medical event in a participant, whether or not caused by the product
Adverse Drug Reaction (ADR)An AE with a reasonable possibility of being caused by the product
Serious AE (SAE)Death, life threat, hospitalisation, persistent disability, congenital anomaly, or other medically important event
SUSARSuspected Unexpected Serious Adverse Reaction, reported urgently to authorities
  • The investigator records every AE and reports SAEs promptly; in India within 24 hours to the sponsor, ethics committee and licensing authority.
  • Causality and expectedness are assessed against the Investigator's Brochure.
  • Follow-up continues until the event resolves or stabilises.

4.8 Monitoring Visits

VisitTypical activities
Site selection / feasibilityCheck patient pool, experience, staff, equipment and timelines
Site initiation (SIV)Train staff on protocol, GCP, CRF and safety reporting; confirm supplies
Routine monitoringSource data verification, consent checks, drug accountability, AE review
Close-outResolve queries, reconcile drug supply, archive documents, final report
  • Risk-based monitoring focuses effort on critical data and processes instead of checking everything equally.

4.9 Data Quality and Management

  • Source Data Verification compares CRF entries with original records such as hospital files.
  • Queries are raised for inconsistent or missing data and answered with a documented correction.
  • Missing data are minimised by design and handled using methods pre-defined in the SAP.
  • Participant identity is protected by coded identifiers; access is limited to authorised staff.
  • Database lock occurs only after all queries are closed and data reviewed.

4.10 Deviations and Serious Breaches

  • Protocol deviation: departure from the approved protocol; documented, assessed for impact and reported as required.
  • Serious breach: a deviation likely to significantly affect participant safety or data integrity; notified to authorities at once.
  • Both trigger root cause analysis and CAPA (corrective and preventive action).
  • Repeat issues at a site lead to retraining, closer monitoring or, in the worst case, site closure.

4.11 Oversight Bodies

  • Ethics Committee (IEC/IRB): reviews protocol, consent form, recruitment material and amendments; supervises ongoing safety.
  • Data Safety Monitoring Board: independent experts who review unblinded safety data and may advise to continue, modify or stop.
  • Regulatory inspections and sponsor audits check compliance and data reliability.
  • In India, trials must be registered in CTRI and ethics committees must be registered with CDSCO.

4.12 Quick Interview Questions

Role of a CRA in one line?

Protect participants and verify that trial data are accurate and follow the protocol and GCP.

Example answer“A Clinical Research Associate monitors trial sites to protect the rights, safety and well-being of participants, and to verify that data are accurate, complete and consistent with the protocol, GCP and regulations. In practice, I would check informed consent, do source data verification, review safety reporting and follow up on issues with the site.”

Blinding vs randomisation?

Randomisation decides who gets which treatment; blinding keeps that decision hidden.

Example answer“Randomisation assigns participants to treatment groups by chance, so the groups are comparable and selection bias is avoided. Blinding keeps the assignment hidden: in a single-blind trial the participant does not know, and in a double-blind trial neither the participant nor the investigator knows. Randomisation prevents selection bias; blinding prevents assessment bias.”

What happens when a participant withdraws?

Respect the decision, document the reason if given, collect permitted final data and inform sponsor and ethics committee.

Example answer“A participant can withdraw at any time without giving a reason and without losing standard care. I would respect the decision, document the date and the reason if offered and, with their consent, complete the end-of-study assessments and safety follow-up. I would update the CRF and inform the sponsor, and the ethics committee where required.”

How do you improve recruitment?

Review eligibility feasibility, support the site with outreach, track screen failures and fix the commonest cause.

Example answer“First I would review the screening logs to find the commonest reason for failure, such as one eligibility criterion that is too strict, and discuss it with the sponsor if needed. I would help the site with referral networks, approved awareness material and patient-friendly visit schedules, track weekly recruitment against target and share what works at high-performing sites.”

Why is SDV needed?

It confirms CRF data match source documents, which makes results credible.

Example answer“Source Data Verification compares the data entered in the CRF with the original source documents, like hospital records and lab reports. It confirms that the data are accurate and complete and that nothing is missing or fabricated, which makes the results credible to regulators. Many sponsors now use risk-based monitoring, focusing SDV on critical data such as primary endpoints and safety.”

AE vs SAE?

An AE is any untoward event; an SAE meets seriousness criteria such as hospitalisation or death.

Example answer“An adverse event is any untoward medical occurrence in a participant, whether or not it is related to the study drug. A serious adverse event results in death, is life-threatening, needs or prolongs hospitalisation, causes persistent disability, or is a congenital anomaly. Under the NDCT Rules, the investigator reports an SAE to the sponsor, the ethics committee and CDSCO within 24 hours.”

What does an interim analysis allow?

Early stop for harm, futility or overwhelming benefit, guided by pre-planned rules.

Example answer“An interim analysis looks at accumulated data before the trial ends, using rules pre-specified in the protocol and usually reviewed by an independent Data Monitoring Committee. It can allow the trial to stop early for safety, futility or clear benefit, or to adjust the sample size. Pre-planned rules protect against bias and false-positive results.”

How do you handle site staff turnover?

Train the newcomer, update delegation and training logs, and monitor the site more closely during transition.

Example answer“I would make sure the new staff member is trained on the protocol and GCP and that the training is documented. I would update the delegation log and site contact list, ensure the outgoing person hands over pending queries, and increase monitoring visits or remote checks during the transition to catch errors early.”

Chapter 5

Quality Assurance

Building quality into the process so that every batch is safe, effective and consistent.

5.1 QA and QC

PointQuality AssuranceQuality Control
FocusSystems and processesSamples and products
NaturePreventiveDetective
ActivitiesSOPs, audits, validation, change control, trainingSampling, testing, release or rejection
Question answeredIs the process capable of making good product?Does this batch meet its specification?

5.2 Good Manufacturing Practice (GMP)

  • Covers premises, equipment, personnel, materials, documentation, production, quality control and distribution.
  • Goal: prevent contamination, mix-ups and errors so product is consistently of the intended quality.
  • India: Schedule M of the Drugs and Cosmetics Rules; other markets follow WHO, EU or US cGMP.
  • Common challenges: training gaps, documentation errors, cross-contamination control and keeping up with revisions.

5.3 Quality Management System

  • A QMS joins document control, training, deviation and CAPA, change control, audits, complaints and risk management.
  • Management review checks that the system works and decides on resources.
  • ICH Q10 describes the pharmaceutical quality system across the product lifecycle.

5.4 Documentation

DocumentUse
SOPStep-by-step approved instruction for a routine task
Master Formula RecordApproved recipe and process for a product
Batch Manufacturing Record (BMR)Record of everything done for one batch, with in-process results
Batch Packaging RecordRecord of packing operations for one batch
LogbooksUse of equipment, cleaning, calibration and maintenance
Specifications and STPsLimits and test methods for materials and products
  • Good documentation practice: write at the time of activity, sign and date, correct with a single line and a reason, never overwrite.

5.5 Deviation, CAPA and Change Control

SystemCore steps
DeviationReport immediately, contain, assess impact, find root cause, decide disposition, close
CAPACorrective action fixes the existing problem; preventive action stops recurrence; check effectiveness later
Change controlPropose, assess quality impact, approve before implementation, execute, verify, update documents
  • Root cause tools: 5 Whys, fishbone (Ishikawa) diagram, fault tree analysis.

5.6 OOS and OOT Results

  • Out of Specification: a result outside the approved limit; triggers a phased laboratory investigation.
  • Phase 1 checks analyst, instrument, calculations and sample handling; retesting follows written rules.
  • If no laboratory error is found, the investigation extends to manufacturing.
  • Out of Trend: a result within limits but unlike earlier data; an early warning of process or stability drift.

5.7 Qualification and Validation

StageMeaning
DQDesign Qualification: design meets user requirements
IQInstallation Qualification: correctly installed as specified
OQOperational Qualification: works across its operating ranges
PQPerformance Qualification: performs consistently under real conditions
  • Qualification applies to equipment and utilities; validation proves a process, cleaning method or analytical method.
  • Process validation lifecycle: process design, process qualification, continued process verification.
  • Analytical method validation checks accuracy, precision, specificity, linearity, range, LOD, LOQ and robustness.
  • Validation Master Plan sets scope, responsibilities and schedule for all validation work.
  • Cleaning validation uses worst-case product, swab and rinse sampling and residue limits.

5.8 Data Integrity

Data must be trustworthy throughout its life. The ALCOA+ principles are the working checklist.

LetterMeaning
AAttributable: who did it and when
LLegible: readable and permanent
CContemporaneous: recorded at the time
OOriginal: first record or a certified true copy
AAccurate: error free and truthful
+Complete, consistent, enduring and available
  • Controls: unique user IDs, role-based access, audit trails switched on, periodic audit-trail review, backup and archival.

5.9 Stability Studies

  • Show how quality changes with time under temperature, humidity and light.
  • Results set shelf life, storage conditions and retest period.
  • Long-term and accelerated conditions follow ICH Q1A by climatic zone; accelerated is usually 40 °C / 75% RH.
  • Bracketing tests only extreme strengths or pack sizes; matrixing tests a planned subset of samples.
  • A stability-indicating method measures the active ingredient without interference from degradants.

5.10 Contamination Control and Cleanrooms

  • Contaminants: physical (particles), chemical (residues, solvents) and microbiological.
  • Cross-contamination is prevented by cleaning procedures, dedicated or segregated equipment, airflow design and pressure differentials.
  • Cleanroom classes (EU Grades A to D, ISO Classes 5 to 8) limit airborne particles; Grade A is for critical aseptic operations.
  • Environmental monitoring includes air and surface sampling, settle plates and particle counts, with alert and action limits.

5.11 Quality Risk Management and QbD

  • ICH Q9 tools: FMEA, HACCP, fault tree analysis, risk ranking.
  • Quality by Design (ICH Q8): define the Quality Target Product Profile, identify Critical Quality Attributes and Critical Process Parameters, then set a design space.
  • Process Analytical Technology uses real-time measurement to control quality during manufacture.
  • Process capability (Cpk) shows how well a process stays within limits; 1.33 or above is commonly expected.

5.12 Audits, Reviews and Supplier Control

  • Internal audits check compliance with SOPs and GMP; supplier audits qualify vendors of raw and packing materials.
  • Risk-based audits give more time to critical processes and past problem areas.
  • Annual Product Quality Review (APQR/PQR) evaluates a year of batches, deviations, complaints and stability to find trends.
  • Quality agreements define responsibilities between manufacturer and contract partner.
  • Complaint handling: log, assess, investigate batch records, decide on recall or CAPA, reply to the customer.

5.13 Quick Interview Questions

What is the main aim of QA?

To prevent defects by controlling the system that makes the product.

Example answer“The main aim of QA is to make sure every product is consistently safe, effective and of the right quality by building quality into the system, not just testing it at the end. QC tests the product, while QA controls the processes, documents, training, change control and deviations so that defects are prevented in the first place.”

Qualification vs validation?

Qualification proves equipment; validation proves a process or method.

Example answer“Qualification proves that equipment, utilities or facilities are installed correctly and work as intended, through DQ, IQ, OQ and PQ. Validation proves that a process, method or system consistently produces results that meet predefined criteria. Qualification comes first, because a process cannot be validated on unqualified equipment.”

Steps after a deviation?

Report, contain, assess impact, find root cause, apply CAPA, close with approval.

Example answer“First, report the deviation immediately and record it. Second, contain it, for example by holding the batch. Third, assess its impact on product quality and on other batches. Fourth, find the root cause using tools like 5 Whys or a fishbone diagram. Fifth, implement CAPA. Finally, check effectiveness and close the deviation with QA approval.”

How do you respond to an OOS result?

Start a laboratory investigation, avoid unplanned retesting, extend to production if needed, and document the conclusion.

Example answer“I would inform my supervisor and QA, and keep the sample and solutions. Phase I is a laboratory investigation covering calculations, instrument, standards and analyst error. If an assignable lab error is found, the result is invalidated and retested as per SOP; if not, the investigation extends to production. Testing until a pass is never allowed, and everything is documented.”

Why is a hold time study done?

To prove how long an intermediate or product can wait between steps without quality loss.

Example answer“A hold time study establishes how long a bulk, an intermediate or cleaned equipment can be held between process steps without affecting quality, for example how long granules can wait before compression. The data support the hold times written in batch records and prevent microbial growth or chemical degradation.”

What makes data attributable?

Each entry shows who made it and when, through unique login or signature.

Example answer“Data are attributable when we can tell who recorded or changed them and when. On paper this is shown by signature and date; in electronic systems, by unique user IDs and audit trails. It is the A of ALCOA+, along with legible, contemporaneous, original and accurate. Sharing logins breaks attributability.”

How do you handle a failed raw material?

Quarantine it, check the CoA and test records, notify the supplier and decide reject, retest or return.

Example answer“I would label and quarantine the material so it cannot be used. Then I would review the test results, the supplier's CoA and the sampling and testing steps to rule out lab error. If the failure is confirmed, I would raise an OOS or deviation, inform the supplier and purchase team, reject or return the material, and review the supplier's performance.”

What does APQR achieve?

Trend review that shows whether the process stays in control and what to improve.

Example answer“The Annual Product Quality Review evaluates all batches of a product made in a year, including test results, deviations, changes, complaints, returns and stability data. It shows trends and confirms whether the process remains in a state of control. It also identifies improvements and shows when revalidation or a specification change is needed.”

Chapter 6

Pharmaceutical Product Management

Taking a product from concept to market and managing it for its full commercial life.

6.1 Role of a Product Manager

  • Owns the strategy and commercial performance of one product or portfolio.
  • Works with R&D, regulatory, medical affairs, supply chain, sales and marketing.
  • Responsible for market research, positioning, pricing input, launch, forecasting and lifecycle plans.
  • Reports sales, share and prescription trends and corrects course when targets are missed.

6.2 Market Analysis

ToolUse
SWOTStrengths, weaknesses, opportunities, threats of the product
SegmentationGroup doctors or patients by specialty, prescribing habit, need
Competitor mappingBrands, strengths, pricing, pipeline, promotion
Primary researchDoctor surveys, patient interviews, advisory boards
Secondary researchIndustry reports, prescription audit data, published studies

6.3 Positioning and Value Proposition

  • Positioning states who the product is for, what problem it solves and why it is better than alternatives.
  • Value proposition is built on proven differences: efficacy, safety, convenience, adherence, cost-effectiveness.
  • Claims must be supported by approved labelling and published evidence.

6.4 Marketing Mix (4Ps)

PPharma meaning
ProductFormulation, strength, pack, evidence and label
PriceCost, competitor prices, payer or price-control rules, value
PlaceDistribution through stockists, hospitals, pharmacies and e-channels
PromotionDoctor detailing, CMEs, digital content, patient education within regulation

6.5 Launch Planning

  • Confirm regulatory approval, label and supply readiness.
  • Define target specialties and geographies; prepare field force training and detailing aids.
  • Engage Key Opinion Leaders for advocacy and speaker programmes.
  • Plan pricing, trade terms and stock build-up with supply chain.
  • Set launch KPIs and a review calendar: sales, share, new prescriptions, repeat rate, doctor feedback.
  • In a new country, adapt to local regulation, language, pricing and partner network.

6.6 Pricing Approaches

ApproachBasis
Cost-plusManufacturing and overhead cost plus a margin
Competitor-basedPrice relative to similar brands
Value-basedBenefit delivered to patients and payers compared with alternatives
Regulated pricingIn India, ceiling prices for scheduled drugs are set by NPPA under DPCO

6.7 Lifecycle Management

  • Introduction, growth, maturity and decline; strategy changes at each stage.
  • Extension options: new strengths, dosage forms or combinations, new indications, new markets.
  • Before patent expiry: build brand loyalty, consider own branded generic, partnerships or authorised generic.
  • Underperforming product: find the cause (access, awareness, competition, price) before changing tactics.

6.8 Forecasting and KPIs

MeasureWhat it tells
Sales value and volumePerformance against forecast
Market sharePosition relative to competitors
Prescription trend (new and repeat)Doctor adoption and loyalty
Net Promoter ScoreLikelihood doctors or patients recommend the product
Marketing ROIRevenue gained per rupee spent on promotion
  • Forecast methods: trend analysis, regression, analogue products and expert input combined.

6.9 Evidence and Competitive Intelligence

  • Real-world evidence and data from hospital records, claims and registries show use outside trials and support value claims.
  • Competitive intelligence draws on regulatory news, trial registries, publications, conferences and field feedback.
  • Insights guide positioning, pricing, lifecycle plans and anticipated competitor moves.

6.10 Compliance in Promotion

  • Promotion must match the approved label and be fair, balanced and verifiable.
  • India follows the Uniform Code for Pharmaceutical Marketing Practices (UCPMP).
  • Gifts and inducements to prescribers are prohibited; educational activities need transparency.
  • Product recall: coordinate with quality and regulatory, inform doctors and trade, protect patients first and brand second.

6.11 Working Across Functions

  • Set clear goals, owners and dates; hold regular cross-functional reviews.
  • Prioritise using urgency and impact (for example Eisenhower matrix or MoSCoW).
  • Resolve conflicts with data; escalate trade-offs early with options.

6.12 Quick Interview Questions

How do you assess the market for a new drug?

Define the segment, size it, study competitors and treatment practice, and test the need through doctor and patient research.

Example answer“I would define the target patient segment and size it using epidemiology data and market databases. Then I would study competitors, their prices and shares, and the current treatment guidelines. I would speak to doctors, pharmacists and patients to understand the unmet need. Together this gives a forecast and helps decide positioning.”

How do you judge launch success?

Compare sales, share, new and repeat prescriptions and doctor feedback with the launch plan.

Example answer“I would compare actual results with the launch plan: sales, market share, new and repeat prescriptions, and the number of doctors prescribing. I would also check stock availability at pharmacies and collect feedback from doctors and the field team. Early repeat prescriptions are a strong sign of real acceptance.”

What do you do if a product underperforms?

Diagnose the reason with data, then adjust targeting, message, access or price.

Example answer“I would first find the real reason using data: low awareness, wrong doctor targeting, a weak message, competition, price or stock gaps. I would talk to the field team and doctors. Then I would act on the root cause, such as refocusing on the right specialists, revising the message or fixing distribution, and track the results monthly.”

Why involve KOLs?

They give clinical insight, credibility and peer education.

Example answer“Key Opinion Leaders are respected experts whose clinical experience and research influence other doctors. They give insight into unmet needs and trial design, add credibility, and educate peers through scientific meetings. All engagement must be ethical and follow the UCPMP code, with no inducements.”

Cost-plus vs value-based pricing?

Cost-plus starts from cost; value-based starts from the benefit to patient and payer.

Example answer“Cost-plus pricing adds a fixed margin on top of the cost of making and marketing the product. Value-based pricing sets the price according to the benefit the product gives patients and payers, such as better outcomes or fewer hospital stays. In India, scheduled formulations are price-capped under the DPCO, which limits pricing freedom.”

How do you respond to patent expiry?

Extend the lifecycle through new forms or indications and protect share through loyalty and generics strategy.

Example answer“Before expiry, I would plan lifecycle management, such as a new extended-release form, a fixed-dose combination or a new indication. I would strengthen brand loyalty through patient support programmes and doctor engagement. Some companies also launch their own authorised generic to retain share once competitors enter.”

Role of RWE?

Shows real practice outcomes, supports payer discussions and label expansion.

Example answer“Real-World Evidence comes from real-world data such as hospital records, registries, insurance claims and patient apps. It shows how a drug performs in routine practice, including patients often excluded from trials. It supports payer decisions, post-marketing safety and sometimes label expansion. It complements randomised trials but does not replace them.”

How do you handle negative doctor feedback?

Listen, collect specifics, involve medical and quality teams, act and report back.

Example answer“I would listen fully without arguing and collect specific details, such as the patient, the batch and what happened. If it involves an adverse event, I would forward it to pharmacovigilance at once; product complaints go to quality. Then I would go back to the doctor with an answer. Handled well, a complaint can build trust.”

Chapter 7

Clinical Data Management and Biostatistics Basics

Turning raw trial data into clean, reliable datasets ready for analysis.

7.1 Data Management Life Cycle

StageKey activities
Start-upData Management Plan, CRF design, database build and testing (UAT)
ConductData entry, validation checks, query management, coding, SAE reconciliation
Close-outFinal review, database lock, data transfer, archival

7.2 CRF and EDC

  • Case Report Form captures protocol-required data; design should be simple, consistent and traceable to the protocol.
  • Electronic Data Capture systems (for example Medidata Rave, Oracle InForm, Veeva EDC) replace paper CRFs.
  • Edit checks fire automatically when data are missing, out of range or inconsistent.
  • Audit trail records who changed what, when and why.

7.3 Query Management and Coding

  • A query asks the site to confirm or correct a data point; it is raised, answered, reviewed and closed.
  • Medical coding uses MedDRA for adverse events and medical history, and WHODrug for medications.
  • SAE reconciliation compares clinical and safety databases to align events, dates and outcomes.

7.4 CDISC Standards

StandardPurpose
CDASHStandard way to collect data on forms
SDTMStandard structure for submitting tabulation datasets
ADaMAnalysis datasets built from SDTM for statistical analysis
Define-XMLMetadata describing datasets
Controlled TerminologyAgreed lists of terms for standard variables

7.5 Biostatistics Essentials

  • Null hypothesis: no difference; p-value is the probability of seeing the result if the null is true; below 0.05 is the usual cut-off.
  • Confidence interval gives the range of plausible values for the true effect.
  • Type I error (false positive) and Type II error (false negative); power is 1 minus Type II error, usually 80% or 90%.
  • Sample size depends on effect size, variability, alpha and power.
  • Intention-to-treat analysis includes everyone as randomised; per-protocol includes only those who followed the protocol.
  • Common endpoints: primary, secondary, surrogate, composite; types of data: continuous, categorical, time-to-event.
  • SAS and R are the standard analysis tools in the industry.

7.6 Database Lock

  • Preconditions: all data entered, queries closed, coding done, reconciliation complete, protocol deviations classified.
  • Sign-off from data management, biostatistics, clinical and quality precedes lock.
  • A locked database is changed only through a documented, approved unlock process.

7.7 Quick Interview Questions

What is a Data Management Plan?

A document describing how data will be collected, checked, coded, reconciled and locked for the study.

Example answer“A Data Management Plan describes how trial data will be handled from start to finish: CRF design, data entry, edit checks, query management, medical coding, SAE reconciliation and database lock. It defines roles, timelines and quality standards, and it is a living document updated whenever the protocol or processes change.”

What is an edit check?

A programmed rule that flags missing or illogical data at entry.

Example answer“An edit check is a programmed rule in the EDC system that checks data at entry. For example, it flags a visit date earlier than the consent date, or a systolic BP entered as 400. The site receives a query and corrects or confirms the value. Edit checks improve data quality early and reduce manual review.”

SDTM vs ADaM?

SDTM organises collected data for submission; ADaM prepares analysis-ready data.

Example answer“SDTM, the Study Data Tabulation Model, organises collected trial data into standard domains such as DM for demographics and AE for adverse events. ADaM, the Analysis Data Model, is derived from SDTM and creates analysis-ready datasets with derived variables like change from baseline. Both are CDISC standards required by the FDA for submissions.”

Why is database lock important?

It freezes the data so that analysis is based on a final, verified dataset.

Example answer“Database lock means freezing the trial database once all data are entered, cleaned, coded and reconciled, and all queries are resolved. After lock, no change can be made without a formal unlock procedure. This ensures the statistical analysis, and any unblinding, is based on a final, verified dataset.”

What is a p-value?

Probability of getting a result at least as extreme as observed if there were truly no effect.

Example answer“A p-value is the probability of getting a result at least as extreme as the one observed if there were truly no difference between the groups. A p-value below 0.05 is usually called statistically significant. But it does not show the size or clinical importance of the effect; for that we look at the effect estimate and its confidence interval.”

Chapter 8

Medical Writing

Writing clear, accurate and compliant scientific and regulatory documents.

8.1 Types of Medical Writing

TypeExamplesAudience
RegulatoryProtocol, CSR, IB, CTD summaries, informed consent form, RMPRegulators and ethics committees
Scientific publicationManuscripts, abstracts, posters, slide decksJournals and conferences
Medical communicationProduct monographs, training material, FAQsHealthcare professionals and sales teams
Patient and publicPlain-language summaries, leaflets, patient diariesPatients
Safety writingCase narratives, PSUR, DSURSafety and regulatory teams

8.2 Key Guidelines

  • ICH E3: structure and content of the Clinical Study Report.
  • ICH E6: GCP expectations for protocol, IB and records; ICH M4 for CTD layout.
  • CONSORT for randomised trials, PRISMA for systematic reviews, STROBE for observational studies.
  • ICMJE recommendations on authorship and ethics; GPP guidelines for company-sponsored publications.
  • Style references such as AMA Manual of Style; follow the sponsor's or journal's style guide.

8.3 Writing Process

  • Understand audience and purpose; collect source data and templates.
  • Outline, draft, then self-check facts against source tables and listings.
  • Quality control: accuracy, consistency, formatting, references, abbreviations.
  • Review cycles with clinical, statistics, regulatory and medical teams; track comments and resolve them.
  • Final approval, publishing and archiving in the document management system.

8.4 Skills and Tools

  • Clear, concise, neutral language; short sentences; consistent terminology.
  • Data interpretation: reading tables, figures, survival curves, forest plots.
  • Tools: MS Word with templates and styles, reference managers, document management systems, basic statistics knowledge.
  • Plagiarism and copyright awareness; originality checks before submission.

8.5 Quick Interview Questions

Role of a regulatory medical writer?

To prepare accurate, well-structured documents that present clinical data for regulatory decisions.

Example answer“A regulatory medical writer prepares documents such as protocols, Investigator's Brochures, clinical study reports and CTD Module 2 summaries. The aim is to present clinical data accurately, clearly and in line with ICH guidelines so that regulators can make decisions. I would work closely with statisticians, clinicians and the regulatory team.”

What does a CSR contain?

Synopsis, ethics, investigators, study plan, patients, efficacy and safety results, discussion and appendices, following ICH E3.

Example answer“A CSR follows the ICH E3 structure. It includes the title page, synopsis, ethics and investigator details, objectives and design, patient disposition, protocol deviations, efficacy and safety results with tables and listings, discussion and conclusions, and appendices such as the protocol, sample CRF and statistical analysis plan.”

How do you ensure accuracy?

Cross-check every figure against source outputs and use a second-person quality check.

Example answer“I cross-check every number in my text against the source tables and listings, and I use a style guide and template so terms stay consistent. After drafting, I do a self-review, and then a second person performs a quality control check against the source. I track every comment and change in a review log.”

What is a plain-language summary?

A short, jargon-free summary of study results written for patients and the public.

Example answer“A plain-language summary explains a study's results in simple, non-technical words for participants and the public. It covers why the study was done, who took part, what was found and what side effects occurred, without any promotion. In the EU, lay summaries are mandatory under the Clinical Trials Regulation.”

Chapter 9

Medical Affairs

The scientific bridge between a company and the medical community.

9.1 Functions

  • Medical Science Liaison (MSL): scientific exchange with Key Opinion Leaders and investigators.
  • Medical information: answers unsolicited product questions with balanced, referenced responses.
  • Publications and evidence generation: planning papers, real-world studies and investigator-initiated trials.
  • Advisory boards and educational events with fair, transparent rules.
  • Review of promotional material for scientific accuracy and compliance.
  • Support for safety, regulatory and market access teams with medical input.

9.2 Compliance Principles

  • Medical and commercial roles stay separate; MSLs do not carry sales targets.
  • Off-label information is shared only in response to unsolicited requests, through approved channels.
  • Honoraria must reflect fair market value and genuine services.
  • All interactions are documented and follow the company code and the UCPMP in India.

9.3 Skills Required

  • Strong clinical and pharmacology knowledge in a therapeutic area.
  • Ability to read and critique clinical studies.
  • Presentation, listening and relationship-building skills.
  • Preferred qualifications: Pharm.D, M.Pharm, MBBS, MD or PhD for senior roles.

9.4 Quick Interview Questions

Role of an MSL?

To exchange scientific information with experts, gather insights and support evidence generation without promoting.

Example answer“A Medical Science Liaison is a scientific expert who builds relationships with key opinion leaders and healthcare professionals. The MSL shares balanced scientific information, answers unsolicited medical questions, gathers insights from the field and supports investigator-initiated studies. The role is non-promotional and carries no sales targets.”

How is Medical Affairs different from marketing?

Medical Affairs is scientific and non-promotional; marketing builds demand within label and regulations.

Example answer“Medical Affairs is the scientific arm: it communicates balanced, evidence-based data, answers medical questions and generates evidence, without promoting the product. Marketing creates demand within the approved label and regulations. The two stay separate so that scientific exchange is never used as promotion.”

What is an unsolicited request?

A question about a product that the healthcare professional raises without prompting from the company.

Example answer“An unsolicited request is a question about a product, often about off-label use, that a healthcare professional raises on their own without any prompting from the company. Medical Affairs may answer it with balanced scientific information limited to that specific question, and both the request and the response are documented.”

Chapter 10

Health Economics, Outcomes Research and Real-World Evidence

Showing value for money and real-life performance of medicines.

10.1 Economic Evaluation Methods

MethodOutcome measuredUsed when
Cost-Minimisation (CMA)Cost onlyOutcomes are equal
Cost-Effectiveness (CEA)Natural units such as cases avoidedCompare treatments with the same outcome unit
Cost-Utility (CUA)QALYsCompare across diseases
Cost-Benefit (CBA)Money for both cost and benefitSociety-level decisions
  • ICER = difference in cost divided by difference in effect between two options.
  • QALY combines length of life and quality of life; DALY measures disease burden.
  • Budget impact analysis estimates the effect on a payer's budget over a few years.

10.2 Real-World Data and Evidence

  • Sources: electronic health records, insurance claims, patient registries, pharmacy data, wearables and surveys.
  • Real-world evidence (RWE) is clinical evidence derived from analysis of real-world data.
  • Uses: label expansion, safety follow-up, comparative effectiveness, payer dossiers and external control arms.
  • Main concerns: confounding, selection bias, missing data and data quality; methods such as propensity scores help.

10.3 Health Technology Assessment

  • HTA reviews clinical, economic and ethical evidence to support coverage and pricing decisions.
  • Examples: NICE (UK), CADTH (Canada); in India, the Health Technology Assessment in India (HTAIn) programme under the Department of Health Research.
  • Value dossiers combine clinical evidence, economic models and real-world data.

10.4 Quick Interview Questions

What is an ICER?

The extra cost per extra unit of benefit when a new treatment is compared with an alternative.

Example answer“ICER, the Incremental Cost-Effectiveness Ratio, is the difference in cost between two treatments divided by the difference in their effects. If a new drug costs ₹50,000 more and gives 0.5 extra QALY, the ICER is ₹1,00,000 per QALY. Payers compare this with a willingness-to-pay threshold to judge value.”

Difference between RCT and RWE?

RCTs test efficacy under controlled conditions; RWE shows effectiveness and safety in routine practice.

Example answer“RCTs test efficacy in a controlled setting with selected patients and randomisation, so they show whether a drug works under ideal conditions. RWE comes from routine care, so it shows effectiveness and safety in wider, more diverse populations over longer periods. RCTs have high internal validity; RWE adds external validity.”

What is a QALY?

A measure that combines years of life gained with the quality of those years.

Example answer“A QALY, or Quality-Adjusted Life Year, combines quantity and quality of life. One year in perfect health equals 1 QALY, and a year with a quality score of 0.5 equals 0.5 QALY. It allows treatments for different diseases to be compared, and it is used in cost-utility analysis.”

Chapter 11

Medical Coding and Healthcare Documentation

Converting medical records into standard codes for billing, research and safety.

11.1 Code Sets

Code setUse
ICD-10-CM / ICD-10Diagnoses and conditions
ICD-10-PCSInpatient procedures (USA)
CPTOutpatient procedures and services (USA)
HCPCSSupplies, drugs and services not in CPT
MedDRA / WHODrugClinical trial and safety coding

11.2 Workflow and Compliance

  • Read the clinical record, identify the principal diagnosis and procedures, assign codes in order, and check coding guidelines.
  • Accuracy, productivity and compliance targets are tracked; audits check for upcoding and missing documentation.
  • HIPAA protects patient information in the USA; India's Digital Personal Data Protection Act 2023 governs personal data.

11.3 Certifications and Career Path

  • Common credentials: CPC (AAPC) and CCS (AHIMA).
  • Pharmacy graduates have an advantage in drug, diagnosis and procedure terminology.
  • Career path: coder, auditor, team lead, quality analyst, trainer.

11.4 Quick Interview Questions

ICD vs CPT?

ICD codes the diagnosis (why); CPT codes the procedure or service (what was done).

Example answer“ICD, the WHO's International Classification of Diseases, codes the diagnosis, which is why the patient was treated; for example, type 2 diabetes is E11 in ICD-10. CPT, Current Procedural Terminology from the American Medical Association, codes what was done, such as a consultation or a surgery. Both are needed for an accurate claim.”

What is upcoding?

Assigning a code for a more serious or costly service than documented; it is non-compliant.

Example answer“Upcoding is assigning a billing code for a more complex or costly service than what was actually provided or documented, such as coding a routine visit as a comprehensive one. It is fraudulent and non-compliant. As a coder, I code only what the documentation supports and query the physician when it is unclear.”

Chapter 12

AI and Digital Skills in Pharma

Data, automation and computerised-system compliance in modern pharma work.

12.1 Where AI and Digital Tools Are Used

AreaUse
Drug discoveryTarget identification, molecule design, virtual screening
Clinical trialsPatient matching, decentralised trials, wearables, eCOA/ePRO
PharmacovigilanceCase intake, duplicate detection, literature screening, signal detection
ManufacturingProcess analytical technology, predictive maintenance, Pharma 4.0
Regulatory and medical writingDrafting support, document comparison, submission tracking
CommercialSegmentation, forecasting, omnichannel engagement

12.2 Compliance with Computerised Systems

  • Computerised System Validation (CSV) and the newer risk-based Computer Software Assurance (CSA) approach prove a system does what it should.
  • GAMP 5 categorises software by complexity and guides validation effort.
  • Data integrity: access control, audit trails, backups, change control, periodic review.
  • 21 CFR Part 11 and EU Annex 11 govern electronic records and signatures.
  • AI use needs human oversight, documented purpose, training-data control and performance monitoring; confirm current regulator guidance before use.

12.3 Skills to Build

  • Excel (lookup, pivot, charts), basic SQL and Python or R.
  • Reading dashboards and understanding data quality.
  • Prompting AI tools carefully, verifying outputs against source documents and never sharing confidential data on public tools.
  • Awareness of data privacy laws including India's DPDP Act 2023.

12.4 Quick Interview Questions

What is CSV?

A documented process showing that a computerised system consistently performs as intended.

Example answer“Computerised System Validation is the documented process of proving that a computerised system used in GxP work, like LIMS or a safety database, consistently does what it is intended to do. It covers user requirements, risk assessment, testing, and data integrity controls such as audit trails, in line with 21 CFR Part 11 and EU Annex 11.”

What does GAMP 5 do?

It gives a risk-based framework to categorise and validate GxP computerised systems.

Example answer“GAMP 5, from ISPE, gives a risk-based approach to validating GxP computerised systems. It groups software into categories, such as Category 1 infrastructure, 3 non-configured, 4 configured and 5 custom, so that validation effort matches risk and complexity. It also stresses supplier involvement and lifecycle management.”

Is AI output accepted without checking in GxP work?

No; a trained person verifies it and the process is documented.

Example answer“No. AI tools can speed up tasks like drafting case narratives or screening literature, but in GxP work a trained person must review and verify the output and remains responsible for it. The tool's use should be risk-assessed, the process documented and confidential data protected. Final decisions always rest with qualified people.”

Chapter 13

Production, Formulation R&D and Analytical QC

Making dosage forms, developing formulations and testing quality in the laboratory.

13.1 Tablet Manufacturing

StepPurpose / note
Dispensing and siftingWeigh materials under line clearance; remove lumps
Blending / granulationWet or dry granulation or direct compression to improve flow and compressibility
Drying and sizingReach target loss on drying; uniform granule size
LubricationAdd lubricant (magnesium stearate) briefly to avoid sticking
CompressionCheck weight variation, hardness, thickness, friability, disintegration
CoatingFilm or sugar coating for taste, stability or release control
PackingStrip, blister or bottle with label and batch coding

13.2 Common Tablet Defects

DefectMeaningUsual cause
CappingTop of tablet separatesExcess fines, low binder, high compression speed
LaminationTablet splits into layersAir entrapment, over-compression
Sticking / pickingMaterial adheres to punch faceDamp granules, insufficient lubricant
MottlingUneven colourColour migration, uneven mixing
Weight variationTablets differ in weightPoor flow, die filling problems

13.3 Other Dosage Forms

  • Capsules: hard gelatin filling, soft gelatin encapsulation; check fill weight and disintegration.
  • Liquid orals: syrups, suspensions and emulsions; control pH, viscosity, preservation and uniformity.
  • Semisolids: ointments, creams and gels; control homogeneity, spreadability and microbial limits.
  • Parenterals: made under aseptic or terminal sterilisation; control sterility, bacterial endotoxin and particulate matter.

13.4 In-Process Controls and Tests

  • Weight variation, hardness, friability (limit not more than 1%), disintegration and dissolution for tablets.
  • Assay and content uniformity for dose accuracy; related substances for impurities.
  • Loss on drying, bulk and tapped density, angle of repose for powders.

13.5 Formulation R&D

  • Preformulation studies: solubility, pKa, polymorphism, compatibility with excipients.
  • Excipient selection and design of experiments for optimisation.
  • Scale-up and technology transfer from lab to pilot to commercial batch.
  • Bioequivalence and dissolution profile comparison (f2 similarity) for generics.
  • Quality by Design principles guide the design space and control strategy.

13.6 Analytical QC

  • Instruments: HPLC, GC, UV-visible spectrophotometer, FTIR, dissolution apparatus, Karl Fischer titrator, balances and pH meters.
  • System suitability, calibration and qualification are required before use.
  • Method validation parameters: accuracy, precision, specificity, linearity, range, LOD, LOQ and robustness.
  • Good laboratory practice: complete raw data, no overwriting, controlled reference standards and out-of-specification procedure.

13.7 Quick Interview Questions

Why is friability tested?

To check whether a tablet can withstand mechanical shock during handling; the weight loss should be within 1%.

Example answer“Friability checks whether tablets can withstand handling, packing and transport without chipping or breaking. Tablets are rotated in a Roche friabilator at 25 rpm for 4 minutes, that is 100 rotations, and weighed before and after. The weight loss should be not more than 1%. It is especially important for uncoated tablets.”

Difference between wet and dry granulation?

Wet granulation uses a liquid binder and drying; dry granulation compacts powder without liquid, used for moisture or heat sensitive drugs.

Example answer“Wet granulation mixes powders with a liquid binder, followed by wet screening, drying and sizing; it gives good flow and content uniformity but does not suit moisture- or heat-sensitive drugs. Dry granulation compacts powders by slugging or roller compaction without any liquid, so it suits moisture-sensitive drugs such as aspirin.”

What is line clearance?

Verification that the area and equipment are free of materials and documents of the previous batch before starting a new one.

Example answer“Line clearance is the check, before starting a new batch or product, that the area and equipment have no materials, labels, documents or product left from the previous batch. Production performs it, QA verifies it, and it is recorded in the batch record. It prevents mix-ups and cross-contamination, which are major causes of recalls.”

Why is magnesium stearate mixed for a short time?

Over-mixing coats particles and can slow disintegration and dissolution.

Example answer“Magnesium stearate is a hydrophobic lubricant. If it is blended too long, it forms a film over the granules and reduces their wettability, which can lower hardness and slow disintegration and dissolution. So it is added at the end and blended for only a few minutes, as per the validated process.”

What is system suitability?

Checks that the chromatographic system is performing adequately before the sample run.

Example answer“System suitability tests check that the chromatographic system, including the instrument, column and mobile phase, is working properly before samples are analysed. Typical parameters are resolution, tailing factor, theoretical plates and the %RSD of replicate standard injections. If system suitability fails, the sample results cannot be reported.”

Chapter 14

Hospital, Clinical and Community Pharmacy

Patient-facing roles where medicine safety is handled every day.

14.1 Hospital Pharmacy

  • Functions: procurement, storage, dispensing, drug information, ward supply, sterile preparation and monitoring.
  • Pharmacy and Therapeutics Committee decides the hospital formulary and drug policies.
  • Unit-dose dispensing and ward stock checks reduce errors.
  • High-alert medicines (insulin, heparin, potassium chloride, chemotherapy) need double checks and clear labels.
  • Look-alike sound-alike drugs are stored apart and labelled with tall-man lettering where possible.

14.2 Clinical Pharmacy Services

  • Medication reconciliation at admission, transfer and discharge.
  • Prescription review for dose, interactions, duplication and renal or hepatic adjustment.
  • Therapeutic drug monitoring for narrow-index drugs such as digoxin, vancomycin and phenytoin.
  • Antimicrobial stewardship: right drug, dose, duration and de-escalation.
  • ADR monitoring and reporting; patient counselling at discharge.

14.3 Community Pharmacy

  • Verify the prescription, dispense accurately, label clearly and counsel on use, storage and side effects.
  • Maintain registers for Schedule H1 and X and keep bills and prescriptions as required.
  • Offer health screening (blood pressure, glucose) and promote adherence.
  • Handle refusals politely: no prescription-only drug without a valid prescription.

14.4 Patient Counselling Points

Medicine typeKey advice
AntibioticsComplete the course; take at fixed intervals; mention allergies
InhalersShow technique; rinse mouth after steroid inhaler
InsulinRotate injection sites; store unopened in refrigerator; know hypoglycaemia signs
AntihypertensivesTake regularly even without symptoms; do not stop suddenly
NSAIDsTake after food; avoid long use without advice
AnticoagulantsRegular tests; report bleeding; tell all doctors

14.5 Quick Interview Questions

What is medication reconciliation?

Comparing the medicines a patient was taking with those ordered to find and fix differences.

Example answer“Medication reconciliation is comparing the medicines a patient was taking at home with those ordered at admission, transfer or discharge, to find and fix discrepancies such as omissions, duplications or wrong doses. As a hospital pharmacist, I would take a full medication history from the patient, family and records, and discuss any difference with the doctor.”

What are high-alert medicines?

Drugs that carry a high risk of serious harm when used in error.

Example answer“High-alert medicines carry a higher risk of serious harm when used in error. Examples are insulin, heparin, concentrated potassium chloride, opioids and chemotherapy drugs. Safety measures include separate storage, clear labelling, standard concentrations and an independent double-check before administration.”

Role of the P&T committee?

To approve the formulary and promote rational, safe and cost-effective use of medicines.

Example answer“The Pharmacy and Therapeutics committee includes doctors, pharmacists, nurses and administrators. It selects drugs for the hospital formulary, develops treatment guidelines and policies, reviews adverse reactions and medication errors, and promotes rational, safe and cost-effective use. The chief pharmacist usually serves as its secretary.”

How do you counsel a patient on a new medicine?

Explain what it is for, how and when to take it, key side effects, what to avoid and when to seek help, then check understanding.

Example answer“For a new metformin prescription I would say: 'This medicine controls your blood sugar. Take one tablet twice a day with or just after meals to avoid stomach upset. You may have mild nausea or loose stools in the first few days. Avoid alcohol, and if you feel very weak or breathless, contact your doctor.' Then I would ask the patient to repeat the key points back to me.”

Chapter 15

Interview and Workplace Skills

How to present what you know: structure, examples and professional conduct.

15.1 STAR Method for Answers

StepWhat to sayTip
SituationBrief contextTwo sentences at most
TaskYour specific responsibilitySay what you were accountable for
ActionSteps you personally tookUse 'I', not 'we', for your part
ResultOutcome with a measure or lessonA number or a clear change
  • Prepare three or four STAR stories from projects, internships or volunteering covering teamwork, problem solving and responsibility.

15.2 Researching a Company

  • Products, therapeutic areas, recent launches and approvals.
  • Manufacturing sites and inspection history from public sources.
  • Competitors, market position and recent news.
  • Prepare two questions that show interest, such as team structure or training in the first six months.

15.3 Explaining Technical Ideas Simply

  • Define in one sentence, then give a daily-life example.
  • Example: bioavailability is the fraction of a dose that reaches blood circulation in active form.
  • Avoid jargon unless the interviewer asks for depth; check understanding by pausing.

15.4 Frequently Asked Questions: How to Build the Answer

QuestionStructure to follow
Why pharmacy / this role?Early interest, experience that confirmed it, link to the role
Your strengths?Two strengths, each with proof from study or work
A weakness?Real but fixable gap, action you are taking, progress so far
Solving a problem?STAR with a measurable result
A mistake you made?Own it, correct it quickly, add a safeguard
Why this company?Specific product or value plus what you can contribute
Where in five years?Skill depth, wider responsibility, link to the company's growth

15.5 Basic Technical Topics for Freshers

  • Dosage forms and routes of administration, with examples.
  • Pharmacokinetics: absorption, distribution, metabolism, excretion; bioavailability and half-life.
  • Common drug interactions, for example warfarin with aspirin, antacids with some antibiotics.
  • GMP, GLP, GCP and what each governs.
  • Pharmacovigilance and adverse drug reaction reporting basics.

15.6 Situational Questions

Suspected error in a prescription

Do: Re-read and cross-check with patient details; stop the dispensing; tell the pharmacist in charge; suggest a correction only if sure; record the incident.

Avoid: Guessing the doctor's intention or quietly changing the dose.

Many tasks at once in a busy pharmacy

Do: Rank by urgency and risk; keep a written list; ask for help early; stay accurate under pressure.

Avoid: Rushing and skipping checks; working on easy tasks first.

Explaining a drug interaction to a patient

Do: Thank the patient for asking; explain in simple words with the likely effect; advise contact with the doctor before any change.

Avoid: Technical jargon or telling the patient to stop a prescribed medicine.

Supervisor points out your mistake

Do: Listen fully, acknowledge, fix at once, find the cause and add a personal check.

Avoid: Defending or blaming others.

Documentation gap found just before an audit

Do: Report to the owner, assess impact, correct through proper late-entry procedure with date and reason, inform quality head.

Avoid: Back-dating or rewriting records.

Chapter 16

Glossary

TermMeaning
ADRAdverse Drug Reaction: a harmful response to a medicine at normal doses.
ALCOA+Attributable, Legible, Contemporaneous, Original, Accurate, plus complete, consistent, enduring, available.
ANDAAbbreviated New Drug Application for generic approval in the USA.
APIActive Pharmaceutical Ingredient: the part of a medicine that produces its effect.
ATCAnatomical Therapeutic Chemical classification of drugs.
BMRBatch Manufacturing Record.
CAPACorrective and Preventive Action.
CDISCClinical Data Interchange Standards Consortium.
CDSCOCentral Drugs Standard Control Organisation, India's national regulator.
CoACertificate of Analysis giving test results for a batch.
CQACritical Quality Attribute of a product.
CRAClinical Research Associate (monitor).
CRFCase Report Form.
CROContract Research Organisation.
CSRClinical Study Report.
CTD / eCTDCommon Technical Document and its electronic form.
DCGIDrugs Controller General of India.
DSMBData Safety Monitoring Board.
DSURDevelopment Safety Update Report.
EDCElectronic Data Capture.
EMAEuropean Medicines Agency.
FDAUnited States Food and Drug Administration.
GCPGood Clinical Practice.
GDPGood Distribution Practice.
GLPGood Laboratory Practice.
GMPGood Manufacturing Practice.
IBInvestigator's Brochure.
ICERIncremental Cost-Effectiveness Ratio.
ICFInformed Consent Form.
ICHInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
ICSRIndividual Case Safety Report.
IEC / IRBIndependent Ethics Committee / Institutional Review Board.
INDInvestigational New Drug application.
KOLKey Opinion Leader.
MAAMarketing Authorisation Application (EU).
MedDRAMedical Dictionary for Regulatory Activities.
MSLMedical Science Liaison.
NDANew Drug Application.
NPPANational Pharmaceutical Pricing Authority, India.
OOS / OOTOut of Specification / Out of Trend.
PBRERPeriodic Benefit-Risk Evaluation Report.
PQR / APQR(Annual) Product Quality Review.
PvPIPharmacovigilance Programme of India.
QALYQuality-Adjusted Life Year.
QbDQuality by Design.
QMSQuality Management System.
REMSRisk Evaluation and Mitigation Strategy (USA).
RMPRisk Management Plan.
RWEReal-World Evidence.
SAESerious Adverse Event.
SAPStatistical Analysis Plan.
SDTM / ADaMCDISC standards for tabulation and analysis datasets.
SMQStandardised MedDRA Query.
SOPStandard Operating Procedure.
SUSARSuspected Unexpected Serious Adverse Reaction.
TMFTrial Master File.
UCPMPUniform Code for Pharmaceutical Marketing Practices, India.
VigiBaseWHO global database of individual case safety reports.

Preparing for TNMRB, RRB Pharmacist or Drug Inspector exams? Join the 100-day course by Kalai Mam.

View the Course →
💬 📸

Login / Sign Up

Sign in with Google -- one tap, no form to fill.